CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|July 1, 2004
Statin therapy should be considered for all patients with type 2 diabetes
A recent study found that atorvastatin at its starting dosage reduces the risk of a first major cardiovascular event in patients with type 2 diabetes, said Helen Colhoun, MD, at the 64th scientific sessions of the American Diabetes Association (ADA) in Orlando.
Advertisement
Advertisement
Related to this article
Onswik is approved to improve glycemic control in adults with Type 2 diabetes and will be available in the United States in the coming months in two concentrations. No information is available on the list price.
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
UCLA research suggests that GLP-1 therapies may protect bone health in Type 2 diabetes patients.
Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.
In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.
Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
When the referral isn't the finish line: Making SDOH programs actually close care gaps
2
Closing the outpatient monitoring gap in cancer
3
FAQ: State PBM reform in 2026—What's new since spring
4
CMS defined a path for medical frailty. Now comes the hard part.
5